BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Diabetes and Endocrinology - Oncology - Radiology and Medical Imaging

Nuclear Factor-Kappa B Inhibition Can Enhance Apoptosis of Differentiated Thyroid Cancer Cells Induced by 131I
Published: Friday, March 16, 2012
Author: Zhaowei Meng et al.

by Zhaowei Meng, Shanshan Lou, Jian Tan, Ke Xu, Qiang Jia, Wei Zheng


To evaluate changes of nuclear factor-kappa B (NF-?B) during radioiodine 131 (131I) therapy and whether NF-?B inhibition could enhance 131I-induced apoptosis in differentiated thyroid cancer (DTC) cells in a synergistic manner.


Three human DTC cell lines were used. NF-?B inhibition was achieved by using a NF-?B inhibitor (Bay 11-7082) or by p65 siRNA transfection. Methyl-thiazolyl-tetrazolium assay was performed for cell viability assessment. DNA-binding assay, luciferase reporter assay, and Western blot were adopted to determine function and expression changes of NF-?B. Then NF-?B regulated anti-apoptotic factors XIAP, cIAP1, and Bcl-xL were measured. Apoptosis was analyzed by Western blot for caspase 3 and PARP, and by flow cytometry as well. An iodide uptake assay was performed to determine whether NF-?B inhibition could influence radioactive iodide uptake.


The methyl-thiazolyl-tetrazolium assay showed significant decrease of viable cells by combination therapy than by mono-therapies. The DNA-binding assay and luciferase reporter assay showed enhanced NF-?B function and reporter gene activities due to 131I, yet significant suppression was achieved by NF-?B inhibition. Western blot proved 131I could increase nuclear NF-?B concentration, while NF-?B inhibition reduced NF-?B concentration. Western blot also demonstrated significant up-regulation of XIAP, cIAP1, and Bcl-xL after 131I therapy. And inhibition of NF-?B could significantly down-regulate these factors. Finally, synergism induced by combined therapy was displayed by significant enhancements of cleaved caspase 3 and PARP from Western blot, and of Annexin V positively staining from flow cytometry. The iodine uptake assay did not show significant changes when NF-?B was inhibited.


We demonstrated that 131I could induce NF-?B activation, which would attenuate 131I efficacy in DTC cells. NF-?B inhibition by Bay 11-7082 or by p65 siRNA transfection was effective in suppressing NF-?B regulated anti-apoptotic changes and in combined regimen apoptosis was achieved synergistically.